Search
Now showing items 1-5 of 5
Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2019 , Article Review)
The treatment of several solid and hematologic malignancies with immune checkpoint inhibitors (against PD-1/PD-L1) has dramatically changed the cancer treatment paradigm. However, no checkpoint inhibitors were previously ...
Epstein-Barr Virus and Human Papillomaviruses Interactions and Their Roles in the Initiation of Epithelial-Mesenchymal Transition and Cancer Progression.
(
Frontiers Media
, 2018 , Article Review)
Oncoviruses are implicated in around 20% of all human cancers including both solid and non-solid malignancies. Epstein-Barr virus (EBV) and human papillomaviruses (HPVs) are the most common oncoviruses worldwide. Currently, ...
Critical appraisal of predatory journals in pathology.
(
BMJ
, 2019 , Article)
Predatory journals refer to journals that recruit articles through aggressive marketing and spam emails, promising a quick, but not robust, review and fast open-access (OA) publication, thus compromising scholarly publishing ...
The Combination of Dasatinib and PD L1 inhibitor prevents the progression of epithelial mesenchymal transition and dramatically blocks cell invasion of HER2 positive breast cancer cells
(
Qatar University Press
, 2021 , Poster)
Introduction: Both Dasatinib (DA), a tyrosine kinase inhibitor that is used for targeted cancer therapy, and programmed death-ligand 1 (PD-1/PD-L1) inhibitor that is an immune checkpoint therapy, play a vital role in the ...
PD-L1 status in breast cancer: Current view and perspectives.
(
Elsevier
, 2019 , Article)
Breast cancer was traditionally not considered a particularly immunogenic tumor. However, recent developments have shown that some aggressive triple-negative breast cancers are immunogenic, exhibit a resistance to chemotherapy ...